EMA
- Health
LEO Pharma Presents Long-Term Safety and Efficacy Data for Tralokinumab in Adults With Moderate-to-Severe Atopic Dermatitis at AAD VMX 2021
Ballerup, Denmark & Madison, N.J., United States: Interim analysis at 56 weeks from ECZTEND, an open-label extension trial, demonstrates sustainable…
Read More » - Business Wire
LEO Pharma Receives Positive CHMP Opinion of Adtralza® (tralokinumab) for the Treatment of Adults With Moderate-to-Severe Atopic Dermatitis
NOT FOR DISTRIBUTION IN THE UK OR IRELAND If authorized, Adtralza® (tralokinumab) will be the first approved biologic that specifically…
Read More » - Business Wire
VFMCRP and Cara Therapeutics announce European Medicines Agency has accepted to review the Marketing Authorization Application for difelikefalin
Companies have successfully submitted the EU regulatory application for marketing authorization for difelikefalin If approved, difelikefalin injection will be the…
Read More » - Health
Orphan Drug Designation Granted to Rezafungin in EU for the Treatment of Invasive Candidiasis
Cambridge, United Kingdom & San Diego, United States: Invasive candidiasis (IC) is characterised as a severe, life-threatening Candida infection of the bloodstream…
Read More »